Shalini Arunogiri

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6065049/publications.pdf

Version: 2024-02-01

687220 552653 39 824 13 26 citations h-index g-index papers 41 41 41 1021 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Coping styles and mental health in response to societal changes during the COVID-19 pandemic. International Journal of Social Psychiatry, 2021, 67, 540-549.	1.6	136
2	Mental health outcomes associated with the use of amphetamines: A systematic review and meta-analysis. EClinicalMedicine, 2019, 16, 81-97.	3.2	91
3	A systematic review of risk factors for methamphetamine-associated psychosis. Australian and New Zealand Journal of Psychiatry, 2018, 52, 514-529.	1.3	68
4	A Roadmap for Integrating Neuroscience Into Addiction Treatment: A Consensus of the Neuroscience Interest Group of the International Society of Addiction Medicine. Frontiers in Psychiatry, 2019, 10, 877.	1.3	64
5	Patient-Reported Outcomes of Treatment of Opioid Dependence With Weekly and Monthly Subcutaneous Depot vs Daily Sublingual Buprenorphine. JAMA Network Open, 2021, 4, e219041.	2.8	55
6	Reorganization of Substance Use Treatment and Harm Reduction Services During the COVID-19 Pandemic: A Global Survey. Frontiers in Psychiatry, 2021, 12, 639393.	1.3	52
7	A Global Survey on Changes in the Supply, Price, and Use of Illicit Drugs and Alcohol, and Related Complications During the 2020 COVID-19 Pandemic. Frontiers in Psychiatry, 2021, 12, 646206.	1.3	47
8	Pregabalin misuseâ€related ambulance attendances in Victoria, 2012–2017: characteristics of patients and attendances. Medical Journal of Australia, 2019, 210, 75-79.	0.8	43
9	Tracing the affordances of long-acting injectable depot buprenorphine: A qualitative study of patients' experiences in Australia. Drug and Alcohol Dependence, 2021, 227, 108959.	1.6	33
10	The Methamphetamine-Associated Psychosis Spectrum: a Clinically Focused Review. International Journal of Mental Health and Addiction, 2020, 18, 54-65.	4.4	29
11	Trends in gammaâ€hydroxybutyrateâ€related harms based on ambulance attendances from 2012 to 2018 in Victoria, Australia. Addiction, 2020, 115, 473-479.	1.7	20
12	Synthetic cannabinoid use disorder: an update for general psychiatrists. Australasian Psychiatry, 2019, 27, 279-283.	0.4	19
13	A study protocol for the N-ICE trial: A randomised double-blind placebo-controlled study of the safety and efficacy of N-acetyl-cysteine (NAC) as a pharmacotherapy for methamphetamine ("iceâ€) dependence. Trials, 2019, 20, 325.	0.7	14
14	Depot buprenorphine during COVID-19 in Australia: Opportunities and challenges. Journal of Substance Abuse Treatment, 2021, 124, 108221.	1.5	13
15	N-acetylcysteine (NAC) for methamphetamine dependence: A randomised controlled trial. EClinicalMedicine, 2021, 38, 101005.	3.2	12
16	Anxiety and substance use disorders: A worrying combination. Australasian Psychiatry, 2015, 23, 382-387.	0.4	11
17	Methamphetamine use and technology-mediated psychosocial interventions: A mini-review. Addictive Behaviors, 2021, 121, 106881.	1.7	11
18	The role of methamphetamines in psychosis-related ambulance presentations. Australian and New Zealand Journal of Psychiatry, 2015, 49, 939-940.	1.3	10

#	Article	IF	CITATIONS
19	Dysfunctional personality beliefs and emotion recognition in individuals with methamphetamine dependence. Addictive Behaviors, 2020, 105, 106336.	1.7	10
20	Challenges in delivering telemedicine to vulnerable populations: experiences of an addiction medical service during COVIDâ€19. Medical Journal of Australia, 2021, 215, 237.	0.8	10
21	Harm reduction and abstinence-based models for treatment of substance use disorders during the COVID-19 pandemic: a global perspective. BJPsych International, 2022, 19, 66-69.	0.8	9
22	Managing attention deficit hyperactivity disorder in adults using illicit psychostimulants: A systematic review. Australian and New Zealand Journal of Psychiatry, 2017, 51, 876-885.	1.3	8
23	Clinical and demographic characteristics of people who smoke versus inject crystalline methamphetamine in Australia: Findings from a pharmacotherapy trial. Drug and Alcohol Review, 2021, 40, 1249-1255.	1.1	8
24	Substance use and borderline personality disorder: fostering hope in the face of complexity. Australasian Psychiatry, 2019, 27, 569-572.	0.4	7
25	Key differences in treatment-seeking stimulant users attending a specialised treatment service: a means of early intervention?. Australasian Psychiatry, 2017, 25, 246-249.	0.4	5
26	Barriers to Accessing Addiction Treatment for Women at Risk of Homelessness. Frontiers in Global Women S Health, 2022, 3, 795532.	1.1	5
27	Managing opioid dependence in pregnancy – a general practice perspective. Australian Family Physician, 2013, 42, 713-6.	0.5	4
28	Should ketamine be used for the clinical treatment of depression?. Australasian Psychiatry, 2016, 24, 381-384.	0.4	3
29	Emotion Recognition and Impulsive Choice in Relation to Methamphetamine Use and Psychosis Symptoms. Frontiers in Psychiatry, 2019, 10, 889.	1.3	2
30	Opioid agonist treatment in the time of fentanyl: What can we learn from emerging evidence?. Drug and Alcohol Review, 2020, 39, 203-204.	1.1	2
31	An audit examining the impact of a training session on interest in prescribing opioid maintenance treatment among psychiatrists and trainees. Australasian Psychiatry, 2014, 22, 94-94.	0.4	1
32	Monitoring emerging prescriptionâ€drug related harms: a comment on Cairns <i>et al</i> . (2018). Addiction, 2019, 114, 571-572.	1.7	1
33	Methamphetamine addiction: do biological rhythms matter, and could they play a role in treatment?. Sleep, 2021, 44, .	0.6	1
34	A systematic review of the effect of ovarian sex hormones on stimulant use in females. Addiction Biology, 2021, 26, e13079.	1.4	1
35	Sleep disturbance in clients attending a specialist addiction clinic. American Journal on Addictions, 2021, 30, 539-542.	1.3	1
36	Poppy seed tea dependence requiring depot buprenorphine treatment. Medical Journal of Australia, 2021, 215, 504-505.	0.8	1

#	Article	IF	CITATIONS
37	Diversity and retention in academic psychiatry. Australian and New Zealand Journal of Psychiatry, 0, , 000486742211066.	1.3	1
38	Comment on Zang et al 2019: The importance of distinguishing between psychotic and general psychiatric symptoms in the context of methamphetamine use. Addiction Biology, 2020, 25, e12776.	1.4	0
39	Alcohol and Cardiovascular Risk. , 2016, , 119-140.		O